PHASE II STUDY BEVACIZUMAK, CETUXIMAB, IRINOTECAN IN COLORECTAL CANCER

贝伐珠单抗、西妥昔单抗、伊立替康治疗结直肠癌的 II 期研究

• 批准号: 7378406
• 负责人: SCOTT H WADLER
• 金额: $ 1.22万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7378406
• 关键词: PHASE; II; STUDY; BEVACIZUMAK; CETUXIMAB

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To evaluate the effect of bevacizumab on time to tumor progression, response rates and overall survival when added to centuximab plus irinotecan or to cetuximab alone in patients with irinotecan-refractory metastatic colorectal cancer.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子弹和调查员（PI）可能已经从其他NIH来源获得了主要资金，因此可以在其他清晰的条目中代表。列出的机构适用于该中心，这不一定是调查员的机构。为了评估贝伐单抗对症状的进展，反应率和总生存时间的影响，当添加到Centuximab加上Irinotecan或单独的西妥昔单抗中，在患有伊立替康 - 再生式转移性结直肠癌的患者中。